NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

The latest price target for IO Biotech (NASDAQ:IOBT) was reported by HC Wainwright & Co. on April 1, 2025. The analyst firm set a price target for $12.00 expecting IOBT to rise to within 12 months ...

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal that combines two of the world's leaders in mRNA treatments.

Financial Square Treasury Instruments Fund FST Shares FTIXX 29.42% Financial Square Government Fund FST Shares FGTXX 15.30% ...